ARS Pharmaceuticals filed a new drug application for Neffy, an experimental epinephrine nasal spray that aims to treat severe allergic reactions, but the regulatory agency decided Sept. 19 to postpone its decision.
“The FDA requested completion of a pharmacokinetic/pharmacodynamic study assessing repeat doses of neffy compared to repeat doses of an epinephrine injection product under allergen-induced allergic rhinitis conditions to support approval,” ARS Pharmaceuticals said in a news release.
ARS Pharmaceuticals President and CEO Richard Lowenthal said he was “very surprised” by the FDA’s request, adding that FDA advisers did not voice concerns about allergen-induced acute rhinitis during a May meeting.
The company said it would conduct the study and plans to file again for approval in early 2024.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
